References
- Hanif F, Muzaffar K, Perveen K, Malhi SM, Simjee SU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18(1):3–9. doi:https://doi.org/10.22034/APJCP.2017.18.1.3
- Quan R, Zhang H, Li Z, Li X. Survival analysis of patients with glioblastoma treated by long-term administration of temozolomide. Medicine (Baltimore). 2020;99(2):e18591. doi:https://doi.org/10.1097/MD.0000000000018591
- Nussbaumer S, Bonnabry P, Veuthey JL, Fleury-Souverain S. Analysis of anticancer drugs: a review. Talanta. 2011;85(5):2265–89. doi:https://doi.org/10.1016/j.talanta.2011.08.034
- Bayat Mokhtari R, Homayouni TS, Baluch N, Morgatskaya E, Kumar S, Das B, Yeger H. Combination therapy in combating cancer. Oncotarget. 2017;8(23):38022–43. doi:https://doi.org/10.18632/oncotarget.16723
- Singh N, Miner A, Hennis L, Mittal S. Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review. Cancer Drug Resist. 2021;4:17–43.
- Lee SY. Temozolomide resistance in glioblastoma multiforme. Genes Dis. 2016;3(3):198–210. doi:https://doi.org/10.1016/j.gendis.2016.04.007
- Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352(10):997–1003. doi:https://doi.org/10.1056/NEJMoa043331
- Zhou W, Wahl DR. Metabolic abnormalities in glioblastoma and metabolic strategies to overcome treatment resistance. Cancers (Basel). 2019;11(9):1231. doi:https://doi.org/10.3390/cancers11091231
- Bocangel DB, Finkelstein S, Schold SC, Bhakat KK, Mitra S, Kokkinakis DM. Multifaceted resistance of gliomas to temozolomide. Clin Cancer Res. 2002;8(8):e2725–e2734.
- Blough MD, Beauchamp DC, Westgate MR, Kelly JJ, Cairncross JG. Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma. J Neurooncol. 2011;102(1):1. doi:https://doi.org/10.1007/s11060-010-0283-9
- Tungmunnithum D, Thongboonyou A, Pholboon A, Yangsabai A. Flavonoids and other phenolic compounds from medicinal plants for pharmaceutical and medical aspects: an overview. Medicines (Basel). 2018;5(3):93. doi:https://doi.org/10.3390/medicines5030093
- Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv Nutr. 2014;5(4):404–417. doi:https://doi.org/10.3945/an.113.005603
- Vinayagam R, Xu B. Antidiabetic properties of dietary flavonoids: a cellular mechanism review. Nutr Metab (Lond). 2015;12:60. doi:https://doi.org/10.1186/s12986-015-0057-7
- Youdim KA, Dobbie MS, Kuhnle G, Proteggente AR, Abbott NJ, Rice-Evans C. Interaction between flavonoids and the blood-brain barrier: in vitro studies. J Neurochem. 2003;85(1):180–92. doi:https://doi.org/10.1046/j.1471-4159.2003.01652.x
- Choi J, Lee DH, Jang H, Park SY, Seol JW. Naringenin exerts anticancer effects by inducing tumor cell death and inhibiting angiogenesis in malignant melanoma. Int J Med Sci. 2020;17(18):3049–3057. doi:https://doi.org/10.7150/ijms.44804
- Chang HL, Chang YM, Lai SC, Chen KM, Wang KC, Chiu TT, Chang FH, Hsu LS. Naringenin inhibits migration of lung cancer cells via the inhibition of matrix metalloproteinases-2 and -9. Exp Ther Med. 2017;13(2):739–744. doi:https://doi.org/10.3892/etm.2016.3994
- Song HM, Park GH, Eo HJ, Lee JW, Kim MK, Lee JR, Lee MH, Koo JS, Jeong JB. Anti-proliferative effect of naringenin through p38-dependent downregulation of cyclin D1 in human colorectal cancer cells. Biomol Ther (Seoul). 2015;23(4):339–44. doi:https://doi.org/10.4062/biomolther.2015.024
- Fujioka K, Greenway F, Sheard J, Ying Y. The effects of grapefruit on weight and insulin resistance: relationship to the metabolic syndrome. J Med Food. 2006;9(1):49–54. doi:https://doi.org/10.1089/jmf.2006.9.49
- Pazhouhi M, Sariri R, Khazaei MR, Moradi MT, Khazaei M. Synergistic effect of temozolomide and thymoquinone on human glioblastoma multiforme cell line (U87MG). J Cancer Res Ther. 2018;14(5):1023–1028. doi:https://doi.org/10.4103/0973-1482.187241
- Jhaveri N, Cho H, Torres S, Wang W, Schönthal AH, Petasis NA, Louie SG, Hofman FM, Chen TC. Noscapine inhibits tumor growth in TMZ-resistant gliomas. Cancer Lett. 2011;312(2):245–52. doi:https://doi.org/10.1016/j.canlet.2011.08.015
- Torres S, Lorente M, Rodríguez-Fornés F, Hernández-Tiedra S, Salazar M, García-Taboada E, Barcia J, Guzmán M, Velasco G. A combined preclinical therapy of cannabinoids and temozolomide against glioma. Mol Cancer Ther. 2011;10(1):90–103. doi:https://doi.org/10.1158/1535-7163.MCT-10-0688
- Lin CJ, Lee CC, Shih YL, Lin TY, Wang SH, Lin YF, Shih CM. Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy. Free Radic Biol Med. 2012;52(2):377–91. doi:https://doi.org/10.1016/j.freeradbiomed.2011.10.487
- Jakubowicz-Gil J, Langner E, Bądziul D, Wertel I, Rzeski W. Apoptosis induction in human glioblastoma multiforme T98G cells upon temozolomide and quercetin treatment. Tumour Biol. 2013;34(4):2367–78. doi:https://doi.org/10.1007/s13277-013-0785-0
- Terpiłowska S, Siwicka-Gieroba D, Siwicki AK. Cell viability in normal fibroblasts and liver cancer cells after treatment with iron (III), nickel (II), and their mixture. J Vet Res. 2018;62(4):535–542. doi:https://doi.org/10.2478/jvetres-2018-0067
- Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70(2):440–6. doi:https://doi.org/10.1158/0008-5472.CAN-09-1947
- Hong X, Chedid K, Kalkanis SN. Glioblastoma cell line-derived spheres in serum‑containing medium versus serum-free medium: a comparison of cancer stem cell properties. Int J Oncol. 2012;41(5):1693–1700. doi:https://doi.org/10.3892/ijo.2012.1592
- St-Coeur P-D, Poitras JJ, Cuperlovic-Culf M, Touaibia M, Morin P. Investigating a signature of temozolomide resistance in GBM cell lines using metabolomics. J Neurooncol. 2015;125(1):91–102. doi:https://doi.org/10.1007/s11060-015-1899-6
- Zhao Z, Jin G, Ge Y, Guo Z. Naringenin inhibits migration of breast cancer cells via inflammatory and apoptosis cell signaling pathways. Inflammopharmacology. 2019;27(5):1021–1036. doi:https://doi.org/10.1007/s10787-018-00556-3
- Cerrato JA, Yung WK, Liu TJ. Introduction of mutant p53 into a wild-type p53-expressing glioma cell line confers sensitivity to Ad-p53-induced apoptosis. Neuro Oncol. 2001;3(2):113–122. doi:https://doi.org/10.1215/S1522851700000430
- Patil V, Pal J, Somasundaram K. Elucidating the cancer-specific genetic alteration spectrum of glioblastoma derived cell lines from whole exome and RNA sequencing. Oncotarget. 2015;6(41):43452–43471. doi:https://doi.org/10.18632/oncotarget.6171
- Shen Y, Du Y, Zhang Y, Pan Y. Synergistic effects of combined treatment with simvastatin and exemestane on MCF-7 human breast cancer cells. Mol Med Rep. 2015;12(1):456–62. doi:https://doi.org/10.3892/mmr.2015.3406
- Khazaei M, Pazhouhi M, Khazaei S. Temozolomide and tranilast synergistic antiproliferative effect on human glioblastoma multiforme cell line (U87MG). Med J Islam Repub Iran. 2019;33:39. doi:https://doi.org/10.34171/mjiri.33.39
- Kanno S, Tomizawa A, Hiura T, Osanai Y, Shouji A, Ujibe M, Ohtake T, Kimura K, Ishikawa M. Inhibitory effects of naringenin on tumor growth in human cancer cell lines and sarcoma S-180-implanted mice. Biol Pharm Bull. 2005;28(3):527–30. doi:https://doi.org/10.1248/bpb.28.527
- Zhang H, Zhong X, Zhang X, Shang D, Zhou YI, Zhang C. Enhanced anticancer effect of ABT-737 in combination with naringenin on gastric cancer cells. Exp Ther Med. 2016;11(2):669–673. doi:https://doi.org/10.3892/etm.2015.2912
- Lee J, Kim DH, Kim JH. Combined administration of naringenin and hesperetin with optimal ratio maximizes the anti-cancer effect in human pancreatic cancer via down regulation of FAK and p38 signaling pathway. Phytomedicine. 2019;58:152762. doi:https://doi.org/10.1016/j.phymed.2018.11.022
- Zandi A, Moini ZT, Ziai S, Khazaei PY, Haji HM. The synergistic effects of the combination of ciprofloxacin and temozolomide on human glioblastoma A-172 cell line. Middle East J Cancer. 2017;8(1):31–38.
- Darzynkiewicz Z. Critical aspects in analysis of cellular DNA content. Curr Protoc Cytom. 2010;Chapter 7:Unit7.2. doi:https://doi.org/10.1002/0471142956.cy0702s52
- Kocyigit A, Koyuncu I, Dikilitas M, Bahadori F, Turkkan B. Cytotoxic, genotoxic and apoptotic effects of naringenin-oxime relative to naringenin on normal and cancer cell lines. Asian Pac J TropBiomed. 2016;6(10):872–880. doi:https://doi.org/10.1016/j.apjtb.2016.08.004
- Cummings BS, Schnellmann RG. Measurement of cell death in mammalian cells. Curr Protoc Pharmacol. 2004;Chapter 12:Unit 12.8.
- Wang J, Wang C, Hu X, Yu C, Zhou L, Ding Z, Zhou M. Gefitinib-mediated apoptosis is enhanced via inhibition of autophagy by chloroquine diphosphate in cutaneous squamous cell carcinoma cells. Oncol Lett. 2019;18(1):368–374. Juldoi:https://doi.org/10.3892/ol.2019.10308
- Crowley LC, Christensen ME, Waterhouse NJ. Measuring survival of adherent cells with the colony-forming assay. Cold Spring Harb Protoc. 2016;2016(8):pdb.prot087171. doi:https://doi.org/10.1101/pdb.prot087171
- Park JH, Jin CY, Lee BK, Kim GY, Choi YH, Jeong YK. Naringenin induces apoptosis through downregulation of Akt and caspase-3 activation in human leukemia THP-1 cells. Food Chem Toxicol. 2008;46(12):3684–3690. doi:https://doi.org/10.1016/j.fct.2008.09.056
- Bozzuto G, Ruggieri P, Molinari A. Molecular aspects of tumor cell migration and invasion. Ann Ist Super Sanita. 2010;46(1):66–80. doi:https://doi.org/10.4415/ANN_10_01_09
- Demuth T, Berens ME. Molecular mechanisms of glioma cell migration and invasion. J Neurooncol. 2004;70(2):217–28. doi:https://doi.org/10.1007/s11060-004-2751-6
- Chen YY, Chang YM, Wang KY, Chen PN, Hseu YC, Chen KM, Yeh KT, Chen CJ, Hsu LS. Naringenin inhibited migration and invasion of glioblastoma cells through multiple mechanisms. Environ Toxicol. 2019;34(3):233–239. doi:https://doi.org/10.1002/tox.22677